跳至主要内容
临床试验/EUCTR2018-001267-22-NL
EUCTR2018-001267-22-NL进行中(未招募)1 期

F18-PSMA-1007 PET for early biochemical recurrence of prostate cancer, comparison with 18F-Fluciclovine.

Radboud University Medical Center0 个研究点目标入组 50 人开始时间: 2018年6月11日最近更新:

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Male

入选标准

  • In order to be eligible to participate in this study, a subject must meet all of the following criteria:
  • - Males = 18 years
  • - Histologically proven adenocarcinoma of the prostate
  • - Prior local treatment with curative intent
  • - Biochemical recurrence with PSA-levels of 0.2-5.0 ug/L
  • - PSA level determined <8 weeks before study participation
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 15
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 35

排除标准

  • A patient will be excluded from participation in the trial if one or more of the following criteria are met:
  • - Contra-indications for PET-CT: claustrophobia or inability to lay still for the duration of the exam.
  • - Other cancer < 2 years prior to biochemical recurrence

研究者

相似试验